Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford(Ludwig-Maximilians-Universität München), Rüdiger Hehlmann(Heidelberg University), Michele Baccarani(University of Bologna), Kimmo Porkka(Helsinki University Hospital), Markus Pfirrmann(Ludwig-Maximilians-Universität München), François Guilhot(Centre Hospitalier Universitaire de Poitiers), Verena Hoffmann(Zimmer Biomet (Germany)), Doris Lindoerfer(Zimmer Biomet (Germany)), Gert J. Ossenkoppele(Dutch Cancer Society), Joëlle Guilhot(Inserm), Gianantonio Rosti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Bengt Simonsson(Uppsala University Hospital), Susanne Saußele(University of Mannheim)
Cited by 497
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k